Steven Petrou

New Capabilities

Leading R&D across four clinical-stage programs

Children with SCN2A and SCN8A developmental and epileptic encephalopathies have never had a drug designed for their condition. They cycle through four or more medications, none approved for their specific genetic disorder, while their seizures persist and their development regresses. Now, for the first time, a targeted therapy has cleared every major hurdle on its way to the U.S. Food and Drug Administration (FDA): the agency accepted Praxis Precision Medicines' application for relutrigine and granted it priority review, setting a decision deadline of September 27, 2026.

Updated Yesterday